<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="96f792e6-f1a2-40ea-88d6-71bf331be77c"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="Human Prescription Drug Label"/>
   <title>Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan HydrobromideÂ  Syrup<br/>
      <br/> (Brompheniramine Maleate 2 mg, Pseudoephedrine Hydrochloride 30 mg, and Dextromethorphan Hydrobromide 10 mg)<br/>
      <br/> Rx only</title>
   <effectiveTime value="20250430"/>
   <setId root="036b587a-7bfe-4149-bd05-34a37e3e84b6"/>
   <versionNumber value="6"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="141250469"/>
            <name>Ascend Laboratories, LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="915628612" root="1.3.6.1.4.1.519.1"/>
                        <name>Alkem Laboratories Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="67877-558" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="67877-558" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="67877-558" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="57970c94-82c4-4480-8589-88bdada55dc8"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20221111"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="67877-558" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Brompheniramine, Pseudoephedrine, Dextromethorphan<suffix/>
                        </name>
                        <formCode code="C42996" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRUP"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Brompheniramine, Pseudoephedrine, Dextromethorphan</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="2" unit="mg"/>
                              <denominator value="5" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="IXA7C9ZN03" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BROMPHENIRAMINE MALEATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="H57G17P2FN" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>BROMPHENIRAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="30" unit="mg"/>
                              <denominator value="5" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6V9V2RYJ8N" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PSEUDOEPHEDRINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="7CUC9DDI9F" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PSEUDOEPHEDRINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="10" unit="mg"/>
                              <denominator value="5" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="9D2RTI9KYH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROMETHORPHAN HYDROBROMIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="7355X3ROTS" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEXTROMETHORPHAN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PDC6A3C0OX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XF417D3PSL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS CITRIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZB9127XOA" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C RED NO. 40</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="A2I8C7HI9T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPARABEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OJ245FE5EU" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM BENZOATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1Q73Q2JULR" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CITRATE, UNSPECIFIED FORM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="118" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="67877-558-17" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20200716"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="473" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="67877-558-16" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20200716"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA210647" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20200716"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CV" code="C48328" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PINK">
                              <originalText>Light pink</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLFLAVOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C73372" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BUTTERSCOTCH" xsi:type="CV">
                              <originalText>BUTTERSCOTCH</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="aa2f6a43-3f06-49ae-9b1d-4700d08d0ca5"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <br/>
                  <paragraph>Brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide syrupÂ is a clear, light pink syrup with a butterscotch flavor.<br/>
                     <content styleCode="bold">Each 5 mL (1 teaspoonful) contains:</content>
                     <br/>Brompheniramine Maleate, USP ----------------- 2 mg<br/>Pseudoephedrine Hydrochloride, USP -------- 30 mg<br/>Dextromethorphan Hydrobromide, USP ------ 10 mg<br/>Alcohol ------------------------------------------- 0.95% v/v<br/>In a palatable, aromatic vehicle. <br/>Inactive Ingredients: dehydrated ethanol, glycerin, sucrose, citric acid anhydrous, spectracol dual FD&amp;C RedÂ No 40, artificial butterscotch flavour, methylparaben, sodium benzoate, propylene glycol, sodium citrateÂ anhydrous and purified water. It may contain 10% sodium citrate solution for pH adjustment. The pH range isÂ between 3.0 and 6.0.</paragraph>
                  <content styleCode="bold"/>
                  <br/>
                  <renderMultiMedia referencedObject="MM1"/>
                  <br/>
                  <br/>
                  <br/>
                  <br/>
                  <renderMultiMedia referencedObject="MM2"/>
                  <paragraph> Â </paragraph>
                  <br/>
                  <br/>
                  <renderMultiMedia referencedObject="MM3"/>
                  <br/>
                  <br/>
                  <paragraph>Antihistamine/Nasal Decongestant/Antitussive syrup for oral administration.</paragraph>
               </text>
               <effectiveTime value="20221111"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>bpd-01.jpg</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="bpd-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM2">
                     <text>bpd-02.jpg</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="bpd-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>bpd-03</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="bpd-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="687327c2-fc8e-417f-98ab-26715c6c70f4"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Brompheniramine maleate is a histamine antagonist, specifically an H<sub>1</sub> -receptor-blocking agent belonging to the alkylamine class of antihistamines. Antihistamines appear to compete with histamine for receptor sites onÂ effector cells. Brompheniramine also has anticholinergic (drying) and sedative effects. Among theÂ antihistaminic effects, it antagonizes the allergic response (vasodilation, increased vascular permeability,Â increased mucus secretion) of nasal tissue. Brompheniramine is well absorbed from the gastrointestinal tract,Â with peak plasma concentration after single, oral dose of 4 mg reached in 5 hours; urinary excretion is the majorÂ route of elimination, mostly as products of biodegradation; the liver is assumed to be the main site of metabolicÂ transformation.</paragraph>
                  <paragraph>Pseudoephedrine acts on sympathetic nerve endings and also on smooth muscle, making it useful as a nasalÂ decongestant. The nasal decongestant effect is mediated by the action of pseudoephedrine on Î±-sympatheticÂ receptors, producing vasoconstriction of the dilated nasal arterioles. Following oral administration, effects areÂ noted within 30 minutes with peak activity occurring at approximately one hour.</paragraph>
                  <paragraph>Dextromethorphan acts centrally to elevate the threshold for coughing. It has no analgesic or addictiveÂ properties. The onset of antitussive action occurs in 15 to 30 minutes after administration and is of long duration.</paragraph>
               </text>
               <effectiveTime value="20221111"/>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="82b8f9a3-716a-4e5b-9d05-13534c16ece3"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS &amp; USAGE</title>
               <text>
                  <br/>
                  <paragraph>For relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or theÂ common cold.</paragraph>
               </text>
               <effectiveTime value="20221111"/>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="49ab3634-e8d2-4a2e-a880-3638031787ad"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <br/>
                  <paragraph>Hypersensitivity to any of the ingredients. Do not use in the newborn, in premature infants, in nursing mothers, orÂ in patients with severe hypertension or severe coronary artery disease. Do not use dextromethorphan inÂ patients receiving monoamine oxidase (MAOI) inhibitors (see <content styleCode="bold">
                        <linkHtml href="#Section_6.4">PRECAUTIONS - Drug Interactions</linkHtml>
                     </content>Â ).<br/> Antihistamines should not be used to treat lower respiratory tract conditions including asthma.</paragraph>
               </text>
               <effectiveTime value="20221111"/>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="6f1ddd49-9cf9-48b8-9206-192e0eac3d86"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <br/>
                  <paragraph>Especially in infants and small children, antihistamines in overdosage may cause hallucinations, convulsions,Â and death.<br/>Antihistamines may diminish mental alertness. In the young child, they may produce excitation.</paragraph>
               </text>
               <effectiveTime value="20221111"/>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="6458dfd6-79ef-4813-9ee6-8252a20a8266"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20221111"/>
               <component>
                  <section ID="Section_6.1">
                     <id root="39fb546d-df8a-4560-9b25-7afdd1fa0983"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>GENERAL PRECAUTIONS</title>
                     <text>
                        <br/>
                        <paragraph>Because of its antihistamine component, brompheniramine maleate, pseudoephedrine hydrochloride andÂ dextromethorphan hydrobromide syrup should be used with caution in patients with a history of bronchialÂ asthma, narrow angle glaucoma, gastrointestinal obstruction, or urinary bladder neck obstruction. Because ofÂ its sympathomimetic component, brompheniramine maleate, pseudoephedrine hydrochloride andÂ dextromethorphan hydrobromide syrup should be used with caution in patients with diabetes,Â hypertension, heart disease, or thyroid disease.</paragraph>
                     </text>
                     <effectiveTime value="20221111"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.2">
                     <id root="0b53094f-1481-4f89-a94f-9c72b01135d3"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>INFORMATION FOR PATIENTS</title>
                     <text>
                        <br/>
                        <paragraph>Patients should be warned about engaging in activities requiring mental alertness, such as driving a car orÂ operating dangerous machinery.</paragraph>
                     </text>
                     <effectiveTime value="20221111"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.4">
                     <id root="5c102df7-3e5e-4092-b882-70571e2a4d51"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>DRUG INTERACTIONS</title>
                     <text>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Monoamine oxidase (MAO) inhibitors</content>
                           <br/>
                           <br/> Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAOÂ inhibitors and products containing dextromethorphan. In addition, MAO inhibitors prolong and intensify theÂ anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine. ConcomitantÂ administration of brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide syrup and MAO inhibitors shouldÂ be avoided (see <content styleCode="bold">
                              <linkHtml href="#Section_4">CONTRAINDICATIONS</linkHtml>
                           </content>).<br/>
                           <br/>
                           <content styleCode="bold"> Central nervous system (CNS) depressants</content>
                           <br/>
                           <br/> Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives,Â tranquilizers, antianxiety agents, etc.).<br/>
                           <br/>
                           <content styleCode="bold">Antihypertensive drugs</content>
                           <br/>
                           <br/> Sympathomimetic may reduce the effects of antihypertensive drugs.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20221111"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.6">
                     <id root="698a31d6-9b5d-4b20-8d03-95404e6169c7"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY</title>
                     <text>
                        <br/>
                        <paragraph>Animal studies of brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphanÂ hydrobromide syrup to assess the carcinogenic and mutagenic potential or the effect on fertility have notÂ been performed.</paragraph>
                     </text>
                     <effectiveTime value="20221111"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.7">
                     <id root="44013edd-6359-415d-8a9f-3a1de86e80a4"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>PREGNANCY</title>
                     <text>
                        <br/>
                        <paragraph>Teratogenic Effects<br/> Pregnancy Category C<br/> Animal reproduction studies have not been conducted with brompheniramine maleate, pseudoephedrineÂ hydrochloride and dextromethorphan hydrobromide syrup. It is also not known whether brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide syrupÂ can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. It should beÂ given to a pregnant woman only if clearly needed.<br/>
                           <br/>Reproduction studies of brompheniramine maleate (a component of brompheniramine maleate,Â pseudoephedrine hydrochloride and dextromethorphan hydrobromide syrup) in rats and mice at doses up to 16 times the maximum human doses have revealed no evidence of impaired fertility or harm to the fetus.</paragraph>
                     </text>
                     <effectiveTime value="20221111"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.9">
                     <id root="1896f160-c253-44e2-a8cf-f5c4c48503ff"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>NURSING MOTHERS</title>
                     <text>
                        <br/>
                        <paragraph>Because of the higher risk of intolerance of antihistamines in small infants generally, and in newborns andÂ prematures in particular, brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphanÂ hydrobromide syrup is contraindicated in nursing mothers.</paragraph>
                     </text>
                     <effectiveTime value="20221111"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.10">
                     <id root="c0587ce2-de11-490d-877d-adfbfb074c22"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>PEDIATRIC USE</title>
                     <text>
                        <br/>
                        <paragraph>Safety and effectiveness in pediatric patients below the age of 6 months have not been established (seeÂ <content styleCode="bold">
                              <linkHtml href="#Section_10">DOSAGE AND ADMINISTRATION</linkHtml>
                           </content>).</paragraph>
                     </text>
                     <effectiveTime value="20221111"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.11">
                     <id root="4d5d0056-65eb-425e-bf66-ceb0f0a2ce41"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>GERIATRIC USE</title>
                     <text>
                        <br/>
                        <paragraph>Clinical studies of brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphanÂ hydrobromide syrup did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, antihistamines are more likely to causeÂ dizziness, sedation, and hypotension in elderly patients. The elderly are also more likely to experience adverseÂ reactions to sympathomimetics.<br/>
                           <br/>In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosingÂ range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitantÂ disease or other drug therapy.</paragraph>
                     </text>
                     <effectiveTime value="20221111"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_7">
               <id root="24a5c89f-193b-41b3-8e9e-c0b1f5742d6e"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <br/>
                  <paragraph>The most frequent adverse reactions to brompheniramine maleate, pseudoephedrine hydrochloride andÂ dextromethorphan hydrobromide syrup are: sedation; dryness of mouth, nose and throat; thickening of bronchial secretions; dizziness. Other adverse reactions may include:</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Dermatologic:</content>
                     </content> Urticaria, drug rash, photosensitivity, pruritus.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Cardiovascular System:</content>
                     </content> Hypotension, hypertension, cardiac arrhythmias, palpitation.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">CNS:</content>
                     </content> Disturbed coordination, tremor, irritability, insomnia, visual disturbances, weakness, nervousness,Â convulsions, headache, euphoria, and dysphoria.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">G.U. System</content>
                     </content>: Urinary frequency, difficult urination.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">G.I. System</content>
                     </content>: Epigastric discomfort, anorexia, nausea, vomiting, diarrhea, constipation.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Respiratory System:</content>
                     </content> Tightness of chest and wheezing, shortness of breath.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Hematologic System:</content>
                     </content> Hemolytic anemia, thrombocytopenia, agranulocytosis.</paragraph>
               </text>
               <effectiveTime value="20221111"/>
            </section>
         </component>
         <component>
            <section ID="Section_9">
               <id root="d8ab8e5f-93cb-4619-990a-41f888d0c314"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <effectiveTime value="20221111"/>
               <component>
                  <section ID="Section_9.1">
                     <id root="31f4a6cd-196f-4b7e-8e19-56de6b8e9e60"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>Signs and Symptoms</title>
                     <text>
                        <br/>
                        <paragraph>Central nervous system effects from overdosage of brompheniramine may vary from depression to stimulation,Â especially in children. Anticholinergic effects may be noted. Toxic doses of pseudoephedrine may result in CNSÂ stimulation, tachycardia, hypertension, and cardiac arrhythmias; signs of CNS depression may occasionally beÂ seen. Dextromethorphan in toxic doses will cause drowsiness, ataxia, nystagmus, opisthotonos, andÂ convulsive seizures.</paragraph>
                     </text>
                     <effectiveTime value="20221111"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_9.2">
                     <id root="5e2d0173-f4bb-4580-a1b6-2a52a5145980"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>Toxic Doses</title>
                     <text>
                        <br/>
                        <paragraph>Data suggest that individuals may respond in an unexpected manner to apparently small amounts of a particularÂ drug. A 2Â½-year-old child survived the ingestion of 21 mg/kg of dextromethorphan exhibiting only ataxia,Â drowsiness, and fever, but seizures have been reported in 2 children following the ingestion of 13 to 17 mg/kg.Â Another 2Â½-year-old child survived a dose of 300 to 900 mg of brompheniramine. The toxic dose ofÂ pseudoephedrine should be less than that of ephedrine, which is estimated to be 50 mg/kg.</paragraph>
                     </text>
                     <effectiveTime value="20221111"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_9.3">
                     <id root="1d6681e8-caec-4d21-908d-47a2a0af2f72"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>Treatment</title>
                     <text>
                        <br/>
                        <paragraph>Induce emesis if patient is alert and is seen prior to 6 hours following ingestion. Precautions against aspirationÂ must be taken, especially in infants and small children. Gastric lavage may be carried out, although in someÂ instances tracheostomy may be necessary prior to lavage. Naloxone hydrochloride 0.005 mg/kg intravenouslyÂ may be of value in reversing the CNS depression that may occur from an overdose of dextromethorphan. CNSÂ stimulants may counter CNS depression. Should CNS hyperactivity or convulsive seizures occur, intravenousÂ short-acting barbiturates may be indicated. Hypertensive responses and/or tachycardia should be treatedÂ appropriately. Oxygen, intravenous fluids, and other supportive measures should be employed as indicated.</paragraph>
                     </text>
                     <effectiveTime value="20221111"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="6f43c682-2956-4549-93a3-3fb924fcb154"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE &amp; ADMINISTRATION</title>
               <text>
                  <br/>
                  <paragraph>Adults and pediatric patients 12 years of age and over: 10 mL (2 teaspoonfuls) every 4 hours. Children 6 to underÂ 12 years of age: 5 mL (1 teaspoonful) every 4 hours. Children 2 to under 6 years of age: 2.5 mL (Â½ teaspoonful)Â every 4 hours. Infants 6 months to under 2 years of age: Dosage to be established by a physician.<br/>
                     <br/>Do not exceed 6 doses during a 24-hour period.</paragraph>
               </text>
               <effectiveTime value="20221111"/>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="566ad697-b15d-42ca-8419-33987f5531df"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <br/>
                  <paragraph>Brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide syrupÂ is a clear, light pink-colored, butterscotch-flavored syrup containing in each 5 mL (1 teaspoonful) brompheniramine maleate 2 mg, pseudoephedrine hydrochloride 30 mg and dextromethorphan hydrobromideÂ 10 mg, available in the following sizes:<br/>
                     <br/>4 fl oz (118 mL) NDC 67877-558-17<br/>1 Pint (473 mL) NDC 67877-558-16<br/>
                     <br/>
                     <content styleCode="bold">RECOMMENDED STORAGE</content>
                     <br/>
                     <content styleCode="bold">Store at 20 Â° to 25 Â°C (68 Â° to 77 Â°F) [See USP Controlled Room Temperature].</content>
                     <br/>
                     <br/>
                     <content styleCode="bold">KEEP TIGHTLY CLOSED</content>
                     <br/>Dispense in a tight, light-resistant container as defined in the USP.<br/>
                     <br/>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Â </content>
                  </paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">Manufactured by:</content>
                     <br/>Alkem Laboratories Ltd.,<br/> Mumbai - 400 013, INDIA.<br/>
                     <content styleCode="bold">Distributed by:</content>
                     <br/>Ascend Laboratories, LLC<br/> Bedminster, NJ 07921</paragraph>
                  <content styleCode="bold">
                     <br/>
                  </content>
                  <br/>
                  <paragraph> Revised: January, 2025<br/> PT 2859-02</paragraph>
               </text>
               <effectiveTime value="20221111"/>
            </section>
         </component>
         <component>
            <section ID="Section_17">
               <id root="844145fc-7ecb-4628-b434-2c7d4b982a31"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <br/>
                  <paragraph>NDC 67877-<content styleCode="bold">558</content>-17<br/>BrompheniramineÂ Maleate,Â PseudoephedrineÂ Hydrochloride andÂ DextromethorphanÂ Hydrobromide Syrup<br/>Each 5 mL (teaspoonful) contains:<br/>Brompheniramine Maleate, USP 2 mg<br/>Pseudoephedrine Hydrochloride, USP 30 mg<br/>Dextromethorphan Hydrobromide, USP 10 mg<br/>Alcohol 0.95% v/v<br/> Rx Only<br/> NET: 4 fl oz (118 mL)<br/> Ascend Laboratories, LLC</paragraph>
                  <br/>
                  <renderMultiMedia referencedObject="MM4"/>
                  <br/>
                  <br/>
                  <paragraph>NDC 67877-<content styleCode="bold">558</content>-16<br/>BrompheniramineÂ Maleate,Â PseudoephedrineÂ Hydrochloride andÂ DextromethorphanÂ Hydrobromide Syrup<br/>Each 5 mL (teaspoonful) contains:<br/>Brompheniramine Maleate, USP 2 mg<br/>Pseudoephedrine Hydrochloride, USP 30 mg<br/>Dextromethorphan Hydrobromide, USP 10 mg<br/>Alcohol 0.95% v/v<br/> Rx Only<br/> NET: 1 Pint (473 mL)<br/> Ascend Laboratories, LLC</paragraph>
                  <paragraph>
                     <content styleCode="bold">Front</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="MM5"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"> Back</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="MM6"/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20221111"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>bpd-container</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="bpd-container.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>bpd-carton-front</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="bpd-carton-front.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>bpd-carton-back</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="bpd-carton-back.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>